ICD-10-CM Billable Code

E71.520

Childhood cerebral X-linked adrenoleukodystrophy

Clinical Classification Guidelines

Medical Intelligence & Overview

Childhood cerebral X-linked adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the nervous system and adrenal glands. It primarily impacts boys and young men, leading to progressive neurological deterioration and hormonal issues. This condition is classified under ICD-10 code E71.520. Understanding the causes, symptoms, diagnosis, and treatment options can help in managing this complex disease effectively.

Causes & Symptoms

Clinical Causes: ALD is caused by a genetic mutation inherited in an X-linked pattern, meaning the defective gene is located on the X chromosome. Fathers do not pass the condition to their sons but can pass the mutated gene to their daughters, who may become carriers. When a son inherits the mutated gene from his mother, it leads to the development of ALD. The main cause is a deficiency of a protein called ABCD1, which impairs the breakdown of very long-chain fatty acids (VLCFA) in the body. The accumulation of VLCFA in tissues, particularly in the brain and adrenal glands, results in the damage characteristic of ALD.

Key Symptoms: Children with this condition often present with early signs that gradually worsen over time. Typical symptoms may include: - Behavioral changes and confusion - Difficulties with coordination and balance - Muscle weakness and stiffness - Vision and hearing problems - Developmental delays or regression - Seizures - Difficulties with speech and swallowing - Adrenal insufficiency symptoms, such as fatigue, weight loss, and low blood pressure These symptoms usually emerge between ages 4 and 10 and worsen progressively, leading to severe neurological impairment.

Diagnostic & Treatment

Diagnosis Path: Diagnosing childhood cerebral ALD involves several steps: - Blood tests to measure VLCFA levels, which are elevated in individuals with ALD - Genetic testing to identify mutations in the ABCD1 gene - Magnetic resonance imaging (MRI) scans to detect demyelination patterns in the brain characteristic of ALD - Adrenal function tests to assess hormonal levels and detect adrenal insufficiency Early diagnosis is crucial for managing symptoms and exploring treatment options, including potential experimental therapies or supportive care.

Treatment Protocols: While there is no cure for ALD, various approaches aim to manage symptoms and slow disease progression: - Bone marrow or stem cell transplants may be considered for early-stage cerebral ALD to halt neurological decline; - Hormone replacement therapy to treat adrenal insufficiency; - Symptomatic treatments include physical therapy, occupational therapy, and speech therapy to support functional abilities; - Medications may be used to manage seizures and behavioral issues; - Emerging therapies and ongoing research focus on gene therapy and enzyme replacement strategies. Multidisciplinary care involving neurologists, endocrinologists, and supportive services is essential for optimal management.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is E71.520 a billable ICD-10 code?
Yes, E71.520 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report E71.520?
Clinical documentation must specify the nature of Childhood cerebral X-linked adrenoleukodystrophy and any associated comorbidities for accurate reporting.

Cite this Clinical Reference